MoonLake Immunotherapeutics (MLTX) Capital Expenditures (2021 - 2025)
MoonLake Immunotherapeutics' (MLTX) quarterly Capital Expenditures came in at $35000.0 in Q1 2025, down 80.11% quarter-over-quarter from $176000.0 in Q4 2024.
MoonLake Immunotherapeutics (MLTX) Capital Expenditures (2021 - 2025) Analysis & Trends
MoonLake Immunotherapeutics' Capital Expenditures history runs 4 years deep, the most recent figure standing at $35000.0 for Q1 2025.
- On a quarterly basis, Capital Expenditures changed N/A year-over-year to $35000.0 in Q1 2025; TTM through Dec 2025 was $35000.0, a 93.27% decrease from a year earlier, with the FY2025 full-year figure at $35000.0, down 93.27% from the prior year.
- Capital Expenditures eased to $35000.0 in Q1 2025 per MLTX's latest filing, from $176000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $344000.0 in Q3 2024 and bottomed at -$2.0 in Q2 2022.
- The 4-year median for Capital Expenditures is $32376.0 (2021), against an average of $81433.9.
- Biggest YoY gain for Capital Expenditures was 100.0% in 2022; the steepest drop was 100.0% in 2022.
- Year by year, Capital Expenditures stood at $50710.0 in 2021, then sank by 100.0% to $1.0 in 2022, then soared by 17599900.0% to $176000.0 in 2024, then tumbled by 80.11% to $35000.0 in 2025.
- Per Business Quant, the three latest MLTX Capital Expenditures figures stand at $35000.0 (Q1 2025), $176000.0 (Q4 2024), and $344000.0 (Q3 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | MoonLake Immunotherapeutics | 1.38 Bn | 1.02 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 35,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 176,000.00 |
| Dec 31, 2024 | 176,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Sep 30, 2024 | 344,000.00 |
| Dec 31, 2022 | 1.00 |
| Dec 31, 2022 | 1.00 |
| Jun 30, 2022 | -2.00 |
| Jun 30, 2022 | -2.00 |
| Mar 31, 2022 | 16,010.00 |
| Mar 31, 2022 | 16,010.00 |
| Dec 31, 2021 | 50,710.00 |
| Dec 31, 2021 | 50,710.00 |
| Sep 30, 2021 | 29,752.00 |
| Sep 30, 2021 | 29,752.00 |